Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Xynomic to Start Two China Pivotal Trials of Novel HDAC Inhibitor

publication date: Jul 31, 2019

Xynomic Pharma, a US-China oncology company, has been approved to conduct two China pivotal trials of its lead drug candidate, abexinostat, a novel HDAC inhibitor. Abexinostat will be tested as a single agent in third-line treatment of diffuse large B-cell lymphoma (DLBCL) and third-line treatment of follicular lymphoma (FL). Xynomic said it expects patient enrollment for the two trials will be completed in 12 months at 24 China hematological cancer hospitals.
Xynomic has already started global pivotal trials of abexinostat for renal cell carcinoma and non-Hodgkin’s lymphoma. More details....

Stock Symbol: (NSDQ: XYNO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.